Neoplasm

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Retrieved on: 
Monday, April 8, 2024
Health, Radiology, Pharmaceutical, Clinical Trials, Oncology, Toxicity, Therapy, Neoplasm, AACR, DNA, Prostate cancer, PSMA, MEK, Pharmaceutical industry

Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to identify synergistic combinations of known anticancer drugs with 177Lu-rhPSMA-10.1 radioligand therapy, and from a preclinical efficacy analysis of the lead novel drug combination for the treatment of prostate cancer.

Key Points: 
  • Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to identify synergistic combinations of known anticancer drugs with 177Lu-rhPSMA-10.1 radioligand therapy, and from a preclinical efficacy analysis of the lead novel drug combination for the treatment of prostate cancer.
  • “Combination approaches are of increasing interest among the medical community, as we know tumors are heterogeneous and some prostate cancer cells do not express PSMA.
  • Results from this preclinical study presented at AACR demonstrated a synergistic therapeutic effect between 177Lu-rhPSMA-10.1 and an MEK inhibitor.
  • This may be due to inhibition of the MEK-MAPK pathway during DNA damage response, resulting in radiosensitization of cancer cells to 177Lu-rhPSMA-10.1.

Advocating for Awareness and Empowerment: Jason Colodne and Colbeck Capital Sponsor the Children's Tumor Foundation NF Summit 2024

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, Friends, Schwannomatosis, Education, Patient, Neoplasm, Research, NF, San Antonio River Walk, Neurofibromatosis, Empowerment, Drug development, CTF, DSM-IV codes, Pharmaceutical industry

Colbeck Capital Management (“Colbeck”) today announced its ongoing support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of the CTF NF Summit 2024, the largest educational gathering in the neurofibromatosis (“NF”) and schwannomatosis community.

Key Points: 
  • Colbeck Capital Management (“Colbeck”) today announced its ongoing support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of the CTF NF Summit 2024, the largest educational gathering in the neurofibromatosis (“NF”) and schwannomatosis community.
  • This year’s summit includes a renewed focus on the role of patients and care advocates in advancing NF research, contributing to CTF’s goal of bringing new treatments to the market.
  • Supporters like Jason Colodne and Colbeck Capital have enabled CTF to continue driving research and awareness through innovative initiatives and events like the NF Summit.
  • More information regarding CTF and NF Summit 2024 can be found at https://www.ctf.org/ .

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.

Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types

Retrieved on: 
Monday, April 8, 2024
General Health, Pharmaceutical, Oncology, Data Management, Biometrics, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Biotechnology, Health, HER2, Database, Prevalence, Pfizer, Intelligence, Patient, Neoplasm, NGS, ERBB2, Research, RNA, Breast, Messenger, Medicine, AACR, Research fellow, Vaccine

Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.
  • These findings may open up potential therapeutic routes for HER2-directed antibody-drug conjugates in several tumor types.
  • In 2022, Seagen (acquired by Pfizer in December 2023) engaged Tempus to investigate cohorts of patients with HER2 RNA expression.
  • As part of the collaboration, Tempus’ computational and real-world evidence teams helped provide insights on the prevalence of HER2 expression in select solid tumors.

Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Patient, Neoplasm, MMAE, AACR, ADC, Mouse, Head, Cancer, NSCLC, Medical imaging

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.
  • “We previously demonstrated that MYTX-011 drives increased internalization and cytotoxicity in tumor cells expressing moderate cMET levels compared to a matched parent ADC in vitro.
  • MYTX-011 was shown to be highly active in cMET+ xenograft models derived from gastric, esophageal and head and neck cancers.
  • Together, these findings provide preclinical proof-of-concept of the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET-expressing malignancies.

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Ovarian cancer, Translocase, 5T4, Cell, NSCLC, Adenocarcinoma, Patient, Neoplasm, Immunoglobulin G, Cancer, Cancer research, Spacecraft, Translation, Abstract, AACR, ADC, Non-small-cell lung cancer, Vaccine

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

Key Points: 
  • Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
  • The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models.
  • Tubulis is leveraging a proprietary suite of platform technologies to build a pipeline of uniquely matched ADC candidates that combine the right targeting molecule, conjugation chemistry and payload to deliver the true therapeutic value of the ADC approach.
  • The company’s lead candidates, both targeting solid tumor indications, are in late-stage preclinical testing, with TUB-040 ready for clinical evaluation.

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Survival, A-DNA, Patient, Neoplasm, DNA, Biology, AACR, Clinical trial, Skin, Medical imaging

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial in patients with oncogene amplified cancers.
  • “Extrachromosomal DNA afford unique advantages to tumors, typically rendering existing therapies ineffective and correlating with poor patient outcomes,” said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio.
  • BBI-355 showed substantial antitumor activity, including complete and durable regressions, in preclinical oncogene amplified models.

Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma

Retrieved on: 
Sunday, April 7, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Bone marrow, CDK7, MDM2, Apoptosis, BH3, CDK, AML, Dana–Farber Cancer Institute, Patient, LPS, Neoplasm, DNA, Cancer, Liposarcoma, Clinical trial, Azacitidine, CDK9, MCL1, Vaccine

The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.

Key Points: 
  • The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.
  • The data demonstrate that BTX-A51 has preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1α and CDK9.
  • “Dedifferentiated liposarcomas (DDLPS) are rare tumors derived from precursors of fat cells which can occur anywhere in the body.
  • Importantly, preliminary in vivo data in an LPS patient-derived xenograft model reveal that BTX-A51 is well-tolerated under conditions that inhibit tumor growth.

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

Retrieved on: 
Sunday, April 7, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, SOC, Melanoma Research, Oncogene, RNA-binding protein, Patient, SVP, Neoplasm, RNA, Cancer, Messenger, Melanoma, Lung cancer, Society, IND, Immortalised cell line, AACR, Breast cancer, RBP, Therapy, Translational medicine, Vaccine

These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .

Key Points: 
  • These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
  • eIF4E is a main regulator and rate limiting factor for protein synthesis and is elevated in many kinds of tumors.
  • Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC.
  • “The ability to target RNA-binding proteins that regulate oncogenes is a powerful modality with the potential to address cancer indications with high unmet need.